Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review
Autoimmune diseases are disorders that destruct or disrupt the body’s own tissues by its own immune system. Several studies have revealed that polymorphisms of multiple genes are involved in autoimmune diseases. Meanwhile, gene therapy has become a promising approach in autoimmune diseases, and clustered regularly interspaced palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) has become one of the most prominent methods. It has been shown that CRISPR-Cas9 can be applied to knock out proprotein convertase subtilisin/kexin type 9 (PCSK9) or block PCSK9, resulting in lowering low-density lipoprotein cholesterol. In other studies, it can be used to treat rare diseases such as ornithine transcarbamylase (OTC) deficiency and hereditary tyrosinemia. However, few studies on the treatment of autoimmune disease using CRISPR-Cas9 have been reported so far. In this review, we highlight the current and potential use of CRISPR-Cas9 in the management of autoimmune diseases. We summarize the potential target genes for immunomodulation using CRISPR-Cas9 in autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 diabetes mellitus (DM), psoriasis, and type 1 coeliac disease. This article will give a new perspective on understanding the use of CRISPR-Cas9 in autoimmune diseases not only through animal models but also in human models. Emerging approaches to investigate the potential target genes for CRISPR-Cas9 treatment may be promising for the tailored immunomodulation of some autoimmune diseases in the near future..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
International Journal of Molecular Sciences - 23(2022), 3, p 1337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Min Ho Lee [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Autoimmune diseases |
|---|
| doi: |
10.3390/ijms23031337 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01755196X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01755196X | ||
| 003 | DE-627 | ||
| 005 | 20240414203652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms23031337 |2 doi | |
| 035 | |a (DE-627)DOAJ01755196X | ||
| 035 | |a (DE-599)DOAJ57dbd4615fa2417b9a2f28804a1450f8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 050 | 0 | |a QD1-999 | |
| 100 | 0 | |a Min Ho Lee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Autoimmune diseases are disorders that destruct or disrupt the body’s own tissues by its own immune system. Several studies have revealed that polymorphisms of multiple genes are involved in autoimmune diseases. Meanwhile, gene therapy has become a promising approach in autoimmune diseases, and clustered regularly interspaced palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) has become one of the most prominent methods. It has been shown that CRISPR-Cas9 can be applied to knock out proprotein convertase subtilisin/kexin type 9 (PCSK9) or block PCSK9, resulting in lowering low-density lipoprotein cholesterol. In other studies, it can be used to treat rare diseases such as ornithine transcarbamylase (OTC) deficiency and hereditary tyrosinemia. However, few studies on the treatment of autoimmune disease using CRISPR-Cas9 have been reported so far. In this review, we highlight the current and potential use of CRISPR-Cas9 in the management of autoimmune diseases. We summarize the potential target genes for immunomodulation using CRISPR-Cas9 in autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 diabetes mellitus (DM), psoriasis, and type 1 coeliac disease. This article will give a new perspective on understanding the use of CRISPR-Cas9 in autoimmune diseases not only through animal models but also in human models. Emerging approaches to investigate the potential target genes for CRISPR-Cas9 treatment may be promising for the tailored immunomodulation of some autoimmune diseases in the near future. | ||
| 650 | 4 | |a CRISPR-Cas9 | |
| 650 | 4 | |a genome editing | |
| 650 | 4 | |a autoimmune diseases | |
| 653 | 0 | |a Biology (General) | |
| 653 | 0 | |a Chemistry | |
| 700 | 0 | |a Jae Il Shin |e verfasserin |4 aut | |
| 700 | 0 | |a Jae Won Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Keum Hwa Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Do Hyeon Cha |e verfasserin |4 aut | |
| 700 | 0 | |a Jun Beom Hong |e verfasserin |4 aut | |
| 700 | 0 | |a Yeoeun Park |e verfasserin |4 aut | |
| 700 | 0 | |a Eugene Choi |e verfasserin |4 aut | |
| 700 | 0 | |a Kalthoum Tizaoui |e verfasserin |4 aut | |
| 700 | 0 | |a Ai Koyanagi |e verfasserin |4 aut | |
| 700 | 0 | |a Louis Jacob |e verfasserin |4 aut | |
| 700 | 0 | |a Seoyeon Park |e verfasserin |4 aut | |
| 700 | 0 | |a Ji Hong Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Lee Smith |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Molecular Sciences |d MDPI AG, 2003 |g 23(2022), 3, p 1337 |w (DE-627)DOAJ00014584X |x 14220067 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:3, p 1337 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms23031337 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/57dbd4615fa2417b9a2f28804a1450f8 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/23/3/1337 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1661-6596 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1422-0067 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 3, p 1337 | ||